Mostrar el registro sencillo del ítem

dc.contributor.author
Buitrago Garcia, Diana  
dc.contributor.author
Ipekci, Aziz Mert  
dc.contributor.author
Heron, Leonie  
dc.contributor.author
Imeri, Hira  
dc.contributor.author
Araujo Chaveron, Lucia  
dc.contributor.author
Arévalo Rodriguez, Ingrid  
dc.contributor.author
Ciapponi, Agustín  
dc.contributor.author
Cevik, Muge  
dc.contributor.author
Hauser, Anthony  
dc.contributor.author
Alam, Muhammad Irfanul  
dc.contributor.author
Meili, Kaspar  
dc.contributor.author
Meyerowitz, Eric A.  
dc.contributor.author
Prajapati, Nirmala  
dc.contributor.author
Qiu, Xueting  
dc.contributor.author
Richterman, Aaron  
dc.contributor.author
Robles Rodriguez, William Gildardo  
dc.contributor.author
Thapa, Shabnam  
dc.contributor.author
Zhelyazkov, Ivan  
dc.contributor.author
Salanti, Georgia  
dc.contributor.author
Low, Nicola  
dc.date.available
2023-11-01T14:24:45Z  
dc.date.issued
2022-05  
dc.identifier.citation
Buitrago Garcia, Diana; Ipekci, Aziz Mert; Heron, Leonie; Imeri, Hira; Araujo Chaveron, Lucia; et al.; Occurrence and transmission potential of asymptomatic and presymptomatic SARSCoV-2 infections: Update of a living systematic review and meta-analysis; Public Library of Science; Plos Medicine; 19; 5; 5-2022  
dc.identifier.issn
1549-1277  
dc.identifier.uri
http://hdl.handle.net/11336/216769  
dc.description.abstract
Background Debate about the level of asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection continues. The amount of evidence is increasing and study designs have changed over time. We updated a living systematic review to address 3 questions: (1) Among people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) What is the infectiousness of asymptomatic and presymptomatic, compared with symptomatic, SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission in a population is accounted for by people who are asymptomatic or presymptomatic? Methods and findings The protocol was first published on 1 April 2020 and last updated on 18 June 2021. We searched PubMed, Embase, bioRxiv, and medRxiv, aggregated in a database of SARSCoV-2 literature, most recently on 6 July 2021. Studies of people with PCR-diagnosed SARS-CoV-2, which documented symptom status at the beginning and end of follow-up, or mathematical modelling studies were included. Studies restricted to people already diagnosed, of single individuals or families, or without sufficient follow-up were excluded. One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was assessed with a bespoke checklist and modelling studies with a published checklist. All data syntheses were done using random effects models. Review question (1): We included 130 studies. Heterogeneity was high so we did not estimate a mean proportion of asymptomatic infections overall (interquartile range (IQR) 14% to 50%, prediction interval 2% to 90%), or in 84 studies based on screening of defined populations (IQR 20% to 65%, prediction interval 4% to 94%). In 46 studies based on contact or outbreak investigations, the summary proportion asymptomatic was 19% (95% confidence interval (CI) 15% to 25%, prediction interval 2% to 70%). (2) The secondary attack rate in contacts of people with asymptomatic infection compared with symptomatic infection was 0.32 (95% CI 0.16 to 0.64, prediction interval 0.11 to 0.95, 8 studies). (3) In 13 modelling studies fit to data, the proportion of all SARS-CoV-2 transmission from presymptomatic individuals was higher than from asymptomatic individuals. Limitations of the evidence include high heterogeneity and high risks of selection and information bias in studies that were not designed to measure persistently asymptomatic infection, and limited information about variants of concern or in people who have been vaccinated. Conclusions Based on studies published up to July 2021, most SARS-CoV-2 infections were not persistently asymptomatic, and asymptomatic infections were less infectious than symptomatic infections. Summary estimates from meta-analysis may be misleading when variability between studies is extreme and prediction intervals should be presented. Future studies should determine the asymptomatic proportion of SARS-CoV-2 infections caused by variants of concern and in people with immunity following vaccination or previous infection. Without prospective longitudinal studies with methods that minimise selection and measurement biases, further updates with the study types included in this living systematic review are unlikely to be able to provide a reliable summary estimate of the proportion of asymptomatic infections caused by SARS-CoV-2.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Public Library of Science  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/  
dc.subject
SARS CoV 2  
dc.subject
Respiratory infections  
dc.subject
Medical risk factors  
dc.subject
Metaanalysis  
dc.subject
COVID-19  
dc.subject
Epidemiology  
dc.subject
Systematic reviews  
dc.subject
SARS  
dc.subject.classification
Epidemiología  
dc.subject.classification
Ciencias de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Occurrence and transmission potential of asymptomatic and presymptomatic SARSCoV-2 infections: Update of a living systematic review and meta-analysis  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2023-10-31T17:49:11Z  
dc.journal.volume
19  
dc.journal.number
5  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
San Francisco  
dc.description.fil
Fil: Buitrago Garcia, Diana. University of Bern; Suiza  
dc.description.fil
Fil: Ipekci, Aziz Mert. University of Bern; Suiza  
dc.description.fil
Fil: Heron, Leonie. University of Bern; Suiza  
dc.description.fil
Fil: Imeri, Hira. University of Bern; Suiza  
dc.description.fil
Fil: Araujo Chaveron, Lucia. Instituto Pasteur; Francia  
dc.description.fil
Fil: Arévalo Rodriguez, Ingrid. Hospital Universitario Ramón y Cajal; España  
dc.description.fil
Fil: Ciapponi, Agustín. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina  
dc.description.fil
Fil: Cevik, Muge. University of St. Andrews; Reino Unido  
dc.description.fil
Fil: Hauser, Anthony. University of Bern; Suiza  
dc.description.fil
Fil: Alam, Muhammad Irfanul. Instituto Pasteur; Francia  
dc.description.fil
Fil: Meili, Kaspar. Universidad de Umea; Suecia  
dc.description.fil
Fil: Meyerowitz, Eric A.. Montefiore Medical Center; Estados Unidos  
dc.description.fil
Fil: Prajapati, Nirmala. Universite Paris-Saclay;  
dc.description.fil
Fil: Qiu, Xueting. Harvard University. Harvard School of Public Health; Estados Unidos  
dc.description.fil
Fil: Richterman, Aaron. University of Pennsylvania; Estados Unidos  
dc.description.fil
Fil: Robles Rodriguez, William Gildardo. Fundación Universitaria de Ciencias de la Salud; Colombia  
dc.description.fil
Fil: Thapa, Shabnam. University of Manchester; Reino Unido  
dc.description.fil
Fil: Zhelyazkov, Ivan. University Of Sheffield (university Of Sheffield);  
dc.description.fil
Fil: Salanti, Georgia. University of Bern; Suiza  
dc.description.fil
Fil: Low, Nicola. University of Bern; Suiza  
dc.journal.title
Plos Medicine  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1371/journal.pmed.1003987  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003987